Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment could swipe share from Eli Lilly's (LLY) rival drug, Trulicity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,